Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's
disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases that
affect millions of people worldwide, with both prevalence and incidence increasing with age …

Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3
clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease
(AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …

Two phase-III clinical trials with anti-amyloid peptide antibodies have met their primary goal,
ie slowing of Alzheimer's disease (AD) progression. However, antibody therapy may not be …